FRC
FRC Logo
Community
Sign InGet Access

Connect With Us

Stay updated with our latest research and insights

Fundamental Research Corp Logo

Highly ranked equity research firm providing institutional grade tools and analysis to all investors worldwide. Trusted by global investors for over 20+ years.

20+ Years
Rate us on TrustpilotLeave a review

Policies

  • Privacy Policy
  • Terms of Service
  • Disclaimer

Company

  • About Us
  • Our Team
  • Contact Us
  • Leave a Review

Resources

  • Videos
  • Research Reports
  • Community
  • FAQ
  • How to use the site

Browse

  • Stock Directory
  • Stock Screener
  • Market Intel Weekly
  • Report Archive

Trackers

  • Congress Trading
  • Senate Trading
  • Congress Net Worth
  • Markets

© 2026 Fundamental Research Corp. All Rights Reserved.

Professional investment research since 2003

Home
Strategies
Intel
Analysis
Community
Company ProfileSunshine Biopharma, Inc.
  • Company Overview
  • Financial Data
  • Peer Comparison
  • Ownership & News
  • Discussion
SBFMW
Sunshine Biopharma, Inc. Stock AnalysisComprehensive stock analysis for Sunshine Biopharma, Inc. (SBFMW) including live price, Snowflake performance metrics, financial statements, and investment research.Stock AnalysisSBFMW
SBFMW
Sunshine Biopharma, Inc.
  • Company Overview
  • Financial Data
  • Peer Comparison
  • Ownership & News
  • Discussion
SBFMW
  1. Home
  2. Stocks
  3. Sunshine Biopharma, Inc.

Sunshine Biopharma, Inc.

🇺🇸SBFMW•NASDAQ

Sunshine Biopharma, Inc.

🇺🇸SBFMW•NASDAQ
Market cap
$4.18M

Your view on SBFMW

Mkt Cap
$4.18M
Your view
Company Overview

Overview

What the company does, where it operates, and who runs it.

About Sunshine Biopharma, Inc.

Industry
Drug Manufacturers - Specialty & Generic
Sector
Healthcare
CEO
Steve N. Slilaty
Headquarters
333 Las Olas Way, Fort Lauderdale, FL, US
Industry
Drug Manufacturers - Specialty & Generic
Sector
Healthcare
CEO
Steve N. Slilaty
Headquarters
333 Las Olas Way, Fort Lauderdale, FL, US
Description

Sunshine Biopharma, Inc. operates as a pharmaceutical and nutritional supplement company primarily dedicated to the research and development of innovative anticancer drugs. The company's pipeline includes Adva-27a, a GEM-difluorinated C-glycoside derivative of podophyllotoxin.

This compound is currently in development to address a broad spectrum of cancers, such as leukemia, lymphoma, and tumors affecting the testicular, lung, brain, prostate, bladder, colon, ovarian, and liver.

Significantly, Adva-27a has also shown effectiveness against multidrug-resistant cancer cells, including those associated with pancreatic cancer, breast cancer, small-cell lung cancer, and uterine sarcoma. Another key therapeutic in development is SBFM-PL4, an anti-coronavirus treatment compound.

In addition to its pharmaceutical endeavors, Sunshine Biopharma offers a range of nutritional supplements, including the Essential 9 tablet and the Essential Calcium-Vitamin D supplement, and continues to develop and market other scientifically-formulated nutritional products.

The company has forged a licensing agreement with the University of Georgia to further the development of its lead anti-coronavirus compound, SBFM-PL4. Sunshine Biopharma, Inc. is based in Pointe-Claire, Canada.

Financial Data

Stock Data

Price chart, volume, and trading data.

Financial Ratios

Profitability, returns, valuation, and leverage ratios.

About this section

Valuation, profitability, liquidity and leverage ratios for Sunshine Biopharma, Inc.. Starting points for Sunshine Biopharma, Inc.: EPS -$26.23, beta 1.31 — an Drug Manufacturers - Specialty & Generic name. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.

Earnings Analysis

EPS history, beat rate, and upcoming earnings reports.

About this section

Reported vs. expected earnings history for Sunshine Biopharma, Inc.. Trailing twelve-month EPS for Sunshine Biopharma, Inc. stands at -$26.23. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.

Wall Street Analyst Estimates

Analysts' price targets, ratings, and revenue and EPS estimates.

Wall Street analysts· not FRC research
Nov 22, 2026
More →

Earnings per share estimates

Per shareThis quarterDec 2026This yearYear to Dec 2026Next yearYear to Dec 2027
Average estimate−$5.80−$39.00−$8.00
Lowest estimate−$5.80−$39.00−$8.00
Highest estimate−$5.80−$39.00−$8.00
Number of analysts111
A year ago−$3.001−$288.001—
Growth vs a year ago———

1The year-ago figure includes one-time items, so growth is not shown.

Revenue estimates

TotalThis quarterDec 2026This yearYear to Dec 2026Next yearYear to Dec 2027
Average estimate$9.80M$35.80M$45.00M
Lowest estimate$9.80M$35.80M$45.00M
Highest estimate$9.80M$35.80M$45.00M
Number of analysts111
A year ago$8.58M$36.31M—
Growth vs a year ago+14.3%−1.4%—

Financial Statements

Income statement, balance sheet, and cash flow statements.

About this section

Income statement, balance sheet and cash flow history for Sunshine Biopharma, Inc.. Sunshine Biopharma, Inc. has reported as a listed company since 2022. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.

Peer Comparison

Comparables

List of peer companies in the same industry.

Peers, the industry, and the funds that hold SBFMW17 companies
Compare SBFMW with its peers, side by sidePremiumRatios, margins, valuation and leverage of the peers below — one table, one glance.Open Comparable Analysis
Peer companies
TickerTypeCompanySectorIndustryMkt cap
BFRIWBiofrontera Inc.HealthcareMedical - Pharmaceuticals$796,653
BHNGFBhang Inc.HealthcareDrug Manufacturers - Specialty & Generic$23,476
IONKFIonic Brands Corp.HealthcareDrug Manufacturers - Specialty & Generic$1,592
MDVLQMedAvail Holdings, Inc.HealthcareMedical - Pharmaceuticals$161
NRSNNeuroSense Therapeutics Ltd.HealthcareBiotechnology$2.4M
SBFMSunshine Biopharma, Inc.HealthcareDrug Manufacturers - Specialty & Generic$4.7M
More Drug Manufacturers - Specialty & Generic companies
TickerTypeCompanySectorExchangeMkt cap
INLBItem 9 Labs Corp.HealthcareOTC$70,181
INMInMed Pharmaceuticals Inc.HealthcareNASDAQ$8.5M
INSDInstadose Pharma Corp.HealthcareOTC$53,193
IPSEFIpsen S.A.HealthcareOTC$9.4B
IPSEYIpsen S.A.HealthcareOTC$61.0B
IRWDIronwood Pharmaceuticals, Inc.HealthcareNASDAQ$778.1M
ISCNFIsracann Biosciences Inc.HealthcareOTC$1,982
ISOLFIsodiol International Inc.HealthcareOTC$4,914
ITHUFiAnthus Capital Holdings, Inc.HealthcareOTC$34.1M
IVIXFInvion LimitedHealthcareOTC$3.2M
IVX.AXInvion LimitedHealthcareASX—
Open Comparable Analysis
Ownership & News

Institutional Ownership

Which funds and firms own the stock.

About this section

Which institutions hold Sunshine Biopharma, Inc., and how their positions are changing. At a $4.2M market value, institutional positions materially move Sunshine Biopharma, Inc.'s register. Top holders, position sizes, and quarter-over-quarter accumulation or distribution from regulatory filings.

Insider Trading

Recent buying and selling by company executives.

About this section

Buying and selling by Sunshine Biopharma, Inc. executives and directors. Shares of Sunshine Biopharma, Inc. have traded between $0.04 and $0.24 over the past 52 weeks — context for the timing of the transactions below. Insider transactions as disclosed to regulators, with role, size and date — the clearest read on how the people running the company are positioned.

News

Latest headlines and market coverage.

About this section

Latest headlines and company announcements for Sunshine Biopharma, Inc.. Coverage tracks Sunshine Biopharma, Inc. within Drug Manufacturers - Specialty & Generic (Healthcare). Press releases and market coverage, newest first.

Discussion

Comments

Comments and replies from FRC members about this company.

No comments yet

Be the first to ask a question or say what you make of Sunshine Biopharma, Inc.

SBFMW AnalysisWeak
Past
1
Growth
1
Health
5
Profit
1
Value
1